3(S)-N-hydroxy-4-(4-((pyrid-2-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide | 256646-59-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3(S)-N-hydroxy-4-(4-((pyrid-2-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide
• 英文别名: N-hydroxy-2,2-dimethyl-4-(4-pyridin-2-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
• CAS: 256646-59-0
• 化学式: C₁₈H₂₁N₃O₅S₂
• 分子量: 423.514
• InChiKey: HSEBQFSMKLZHPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Inhibitors of Hepatitis C virus, compositions and treatments using the same
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：US20040229817A1

  公开（公告）日：2004-11-18

  The invention relates to methods of inhibiting HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor, and compositions comprising the same.

  本发明涉及一种抑制丙型肝炎病毒复制活性的方法，包括将丙型肝炎病毒聚合酶与治疗有效量的羟肟酸基金属蛋白酶抑制剂接触，并包括这种组合物。
• COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1098662A2

  公开（公告）日：2001-05-16
• INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：PFIZER INC.

  公开号：EP1596846A2

  公开（公告）日：2005-11-23
• Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20040235952A1

  公开（公告）日：2004-11-25

  The invention relates to methods of inhibiting SARS-related coronavirus viral replication activity comprising contacting a SARS-related coronavirus protease with a therapeutically effective amount of a rhinovirus protease inhibitor, and compositions comprising the same.
• [EN] COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS<br/>[FR] CO-ADMINISTRATION D'INHIBITEURS DE ACAT ET DE MMP POUR LE TRAITEMENT DE LESIONS ATHEROSCLEREUSES
  申请人：WARNER LAMBERT CO

  公开号：WO2000004892A2

  公开（公告）日：2000-02-03

  This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal.